Highland Capital Management Fund Advisors, L.P. Uni Qure N.V. Transaction History

Highland Capital Management Fund Advisors, L.P.

$761 Million
Q2 2024

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$20.24 - $36.01 $471,814 - $839,429	-23,311 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$26.01 - $38.22 $1.21 Million - $1.78 Million	-46,689 Reduced 66.7%	23,311 $746,000
Q2 2021 Aug 16, 2021	BUY	$29.97 - $37.17 $2.1 Million - $2.6 Million	70,000 New	70,000 $2.16 Million
Q3 2020 Nov 16, 2020	SELL	$35.98 - $47.66 $190,693 - $252,597	-5,300 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$37.13 - $74.62 $25,991 - $52,234	-700 Reduced 11.67%	5,300 $380,000
Q3 2019 Nov 14, 2019	BUY	$39.36 - $76.8 $236,160 - $460,800	6,000 New	6,000 $236,000

Others Institutions Holding QURE

# of Institutions

142

Shares Held

35.3M

Call Options Held

1.54M

Put Options Held

389K

View Full List

About uniQure N.V.

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $300M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

More about QURE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Highland Capital Management Fund Advisors, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Highland Capital Management Fund Advisors, L.P. with notifications on news.

Account